In this context, we reviewed the existing literature focusing on the development and utility of radiopharmaceuticals binding TSPO in patients affected by PD and how the quantification of microglial activation through PET imaging can affect the diagnosis, treatment and follow-up of patients affected by these neurodegenerative disorders. The gene discussed is TSPO; the disease is Parkinson disease.